Chinese regulator grants second approval for lung cancer drug ivonescimab, which has outperformed Merck’s Keytruda in phase three trial.
China’s Akeso, hailed as biotech’s ‘DeepSeek moment’, falls despite nod for cancer drug
RELATED ARTICLES
Trump China tariff policy ill-suited to supply chain problems, US panel told
With 50 years of history, Manila and Beijing should do better diplomacy
‘At least we’re not out of business’: Small companies in the Trump tariff era
